Literature DB >> 10961585

Catastrophic antiphospholipid syndrome.

R A Asherson1, R Cervera.   

Abstract

In its classic presentation, the antiphospholipid syndrome manifests a combination of venous or arterial thrombosis and fetal loss, accompanied by elevations of antibodies directed toward negatively charged phospholipids, as measured by anticardiolipin antibody assays and/or positive lupus anticoagulant tests. The manifestations often include a moderate thrombocytopenia and, less commonly, hemolysis. In contrast, a less frequently encountered subset of the antiphospholipid syndrome, termed the "catastrophic" antiphospholipid syndrome, affects mainly small vessels predominantly supplying organs. The thrombocytopenia is usually marked, and a Coombs positive microangiopathic-type anemia may accompany the condition. Features of disseminated intravascular coagulation may be evident in some patients. It is fatal in approximately 50% of cases reported. Treatment should include not only adequate anticoagulation with intravenous heparin but also full doses of intravenous corticosteroids, to offset the systemic inflammatory response syndrome that occurs as a result of the extensive tissue damage, and plasmapheresis, using fresh frozen plasma. Parenteral antibiotics should be administered early if infection is suspected.

Entities:  

Mesh:

Year:  2000        PMID: 10961585     DOI: 10.1097/00062752-200009000-00012

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  6 in total

Review 1.  Clinical and laboratory features of the catastrophic antiphospholipid syndrome.

Authors:  Ljudmila Stojanovich; Dragomir Marisavljevic; Jozef Rovensky; Aleksandra Djokovich; Darina Kozáková; Nikola Milinic
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

2.  Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome.

Authors:  R Cervera; J Font; J A Gómez-Puerta; G Espinosa; M Cucho; S Bucciarelli; M Ramos-Casals; M Ingelmo; J-C Piette; Y Shoenfeld; R A Asherson
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

3.  IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.

Authors:  G H Stummvoll; M Aringer; J S Smolen; S Schmaldienst; E Jiménez-Boj; W H Hörl; W B Graninger; K Derfler
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

Review 4.  Catastrophic antiphospholipid syndrome: a clinical review.

Authors:  Ali Nayer; Luis M Ortega
Journal:  J Nephropathol       Date:  2014-01-01

5.  Massive gangrene of the stomach due to primary antiphospholipid syndrome: report of two cases.

Authors:  Vivek Srivastava; Somprakas Basu; Mumtaz Ansari; Saroj Gupta; Anand Kumar
Journal:  Surg Today       Date:  2010-01-28       Impact factor: 2.549

6.  Catastrophic antiphospholipid syndrome presenting as bilateral central retinal artery occlusions.

Authors:  Steven S Saraf; Yogin P Patel; Ankit Desai; Uday R Desai
Journal:  Case Rep Ophthalmol Med       Date:  2015-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.